Venus Remedies Limited (VENUSREM.NS)
INR 311.5
(1.85%)
INR 311.5
(1.85%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.39 Billion INR | -1.04% |
| 2022 | 1.4 Billion INR | 0.98% |
| 2021 | 1.39 Billion INR | -10.41% |
| 2020 | 1.55 Billion INR | -50.51% |
| 2019 | 3.14 Billion INR | -21.47% |
| 2018 | 4 Billion INR | 2.92% |
| 2017 | 3.88 Billion INR | 3.03% |
| 2016 | 3.77 Billion INR | -6.83% |
| 2015 | 4.05 Billion INR | 5.42% |
| 2014 | 3.84 Billion INR | 3.12% |
| 2013 | 3.72 Billion INR | 10.14% |
| 2012 | 3.38 Billion INR | 26.88% |
| 2011 | 2.66 Billion INR | 19.11% |
| 2010 | 2.23 Billion INR | 25.17% |
| 2009 | 1.78 Billion INR | 13.16% |
| 2008 | 1.58 Billion INR | 32.74% |
| 2007 | 1.19 Billion INR | 18.59% |
| 2006 | 1 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.66 Billion INR | 134.1% |
| 2024 Q1 | -4.87 Billion INR | -450.05% |
| 2023 FY | 1.39 Billion INR | -1.04% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 1.69 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 1.39 Billion INR | 0.0% |
| 2022 FY | 1.4 Billion INR | 0.98% |
| 2022 Q4 | 1.4 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 1.31 Billion INR | 0.0% |
| 2021 Q2 | 1.72 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 1.39 Billion INR | -10.41% |
| 2021 Q4 | 1.39 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 2.14 Billion INR | 0.0% |
| 2020 FY | 1.55 Billion INR | -50.51% |
| 2020 Q4 | 1.55 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 3.14 Billion INR | -21.47% |
| 2019 Q2 | 3.77 Billion INR | 0.0% |
| 2019 Q4 | 3.14 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 4 Billion INR | 2.92% |
| 2018 Q4 | 4 Billion INR | 0.0% |
| 2017 FY | 3.88 Billion INR | 3.03% |
| 2016 FY | 3.77 Billion INR | -6.83% |
| 2016 Q4 | 3.77 Billion INR | 0.0% |
| 2015 FY | 4.05 Billion INR | 5.42% |
| 2014 FY | 3.84 Billion INR | 3.12% |
| 2013 FY | 3.72 Billion INR | 10.14% |
| 2013 Q4 | 3.72 Billion INR | 0.0% |
| 2012 Q2 | 578.03 Million INR | 0.0% |
| 2012 FY | 3.38 Billion INR | 26.88% |
| 2012 Q4 | 3.38 Billion INR | 0.0% |
| 2011 FY | 2.66 Billion INR | 19.11% |
| 2010 FY | 2.23 Billion INR | 25.17% |
| 2009 FY | 1.78 Billion INR | 13.16% |
| 2008 FY | 1.58 Billion INR | 32.74% |
| 2007 FY | 1.19 Billion INR | 18.59% |
| 2006 FY | 1 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Hester Biosciences Limited | 3.59 Billion INR | 61.254% |
| RPG Life Sciences Limited | 1.38 Billion INR | -0.913% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | 31.532% |
| Ipca Laboratories Limited | 33.74 Billion INR | 95.872% |
| Aarti Drugs Limited | 11.5 Billion INR | 87.893% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 83.119% |
| Albert David Limited | 1.15 Billion INR | -21.102% |
| Alembic Limited | 1.43 Billion INR | 2.744% |
| Alkem Laboratories Limited | 48.6 Billion INR | 97.134% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 91.441% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -113.528% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 71.387% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -382.273% |
| Brooks Laboratories Limited | 248.6 Million INR | -460.255% |
| Eris Lifesciences Limited | 38.26 Billion INR | 96.36% |
| FDC Limited | 3.7 Billion INR | 62.45% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 73.117% |
| Gufic Biosciences Limited | 5.59 Billion INR | 75.128% |
| Hikal Limited | 12.99 Billion INR | 89.282% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | 39.165% |
| Ind-Swift Limited | 13.45 Billion INR | 89.647% |
| Innova Captab Limited | 4.89 Billion INR | 71.575% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 77.993% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -369.335% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 97.727% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -116.313% |
| Laurus Labs Limited | 42.71 Billion INR | 96.739% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -29.618% |
| Lupin Limited | 96.23 Billion INR | 98.553% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | 29.525% |
| Medico Remedies Limited | 438.24 Million INR | -217.814% |
| Morepen Laboratories Limited | 4.45 Billion INR | 68.77% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 87.584% |
| Orchid Pharma Limited | 3.84 Billion INR | 63.768% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 45.619% |
| Sigachi Industries Limited | 2.53 Billion INR | 44.976% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 90.116% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.241% |
| Themis Medicare Limited | 1.88 Billion INR | 26.21% |
| Unichem Laboratories Limited | 8.06 Billion INR | 82.739% |
| Vaishali Pharma Limited | 371.16 Million INR | -275.253% |
| Wanbury Limited | 3.15 Billion INR | 55.861% |
| Windlas Biotech Limited | 1.76 Billion INR | 20.985% |
| ZIM Laboratories Limited | 2.08 Billion INR | 33.063% |
| Sakar Healthcare Limited | 1.26 Billion INR | -10.253% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 99.085% |
| Divi's Laboratories Limited | 18.99 Billion INR | 92.666% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 61.957% |
| Mankind Pharma Limited | 23.87 Billion INR | 94.166% |
| Sequent Scientific Limited | 8.27 Billion INR | 83.167% |
| Neuland Laboratories Limited | 5.49 Billion INR | 74.67% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 86.993% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 97.861% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 98.06% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -77.693% |
| Wockhardt Limited | 39.87 Billion INR | 96.507% |
| Bal Pharma Limited | 2.51 Billion INR | 44.538% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.698% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | 33.955% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -771.639% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 60.269% |
| Shilpa Medicare Limited | 12.93 Billion INR | 89.23% |
| Valiant Laboratories Limited | 1.05 Billion INR | -31.612% |
| Ajanta Pharma Limited | 10.71 Billion INR | 86.996% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 19.126% |
| Granules India Limited | 22.95 Billion INR | 93.932% |
| Medicamen Biotech Limited | 940.36 Million INR | -48.112% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -19.532% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.751% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 98.302% |
| NATCO Pharma Limited | 10.53 Billion INR | 86.776% |
| Suven Life Sciences Limited | 148.62 Million INR | -837.149% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 53.166% |
| Strides Pharma Science Limited | 37.68 Billion INR | 96.304% |
| Indoco Remedies Limited | 10.34 Billion INR | 86.533% |
| Alpa Laboratories Limited | 307.12 Million INR | -353.501% |
| Lasa Supergenerics Limited | 541.92 Million INR | -157.01% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 64.222% |